Pafolacianine, sold under the brand name Cytalux, is an optical imaging agent used in fluorescence-guided surgery.

[8] Pafolacianine is indicated as an adjunct for intraoperative identification of malignant lesions in people with ovarian cancer.

[2][4] Of the 134 women (ages 33 to 81 years) who received a dose of pafolacianine and were evaluated under both normal and fluorescent light during surgery, 26.9% had at least one cancerous lesion detected that was not observed by standard visual or tactile inspection.

[2][4] The safety and effectiveness of pafolacianine was evaluated in a randomized, multicenter, open-label study (NCT04241315) of participants with known or suspected lung cancer who were scheduled to undergo surgery.

[3] Of the 110 participants who received a dose of pafolacianine and were evaluated under both normal and fluorescent light during surgery, 24% had at least one cancerous lesion detected that was not observed by standard visual or tactile inspection.